From the Department of Medicine, Maternal Fetal Medicine-Cardiology Joint Program at Montefiore Health System, Albert Einstein College of Medicine, Bronx, NY.
Department of Cardiology, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY.
Cardiol Rev. 2022;30(1):31-37. doi: 10.1097/CRD.0000000000000370.
Fetal supraventricular tachycardia management is challenging, with consequences for both the fetus and the mother. If left untreated, fetal hydrops may ensue, at which point delivery and treatment of the arrhythmia is preferred. However, if the fetus is not at term nor near-term, significant doses of antiarrhythmics may be needed to achieve adequate transplacental bioavailability. Although digoxin has classically been the mainstay of treatment, the use of flecainide or sotalol as monotherapy or in combination with digoxin is being studied. Interdisciplinary team management and shared decision-making between the physician and patient are key to achieving successful outcomes. Adult cardiologists, particularly inpatient consultation services or through burgeoning cardio-obstetrics programs, may, in some practice settings, be asked to evaluate or comanage pregnant women with fetal arrhythmia.
胎儿室上性心动过速的管理具有挑战性,对胎儿和母亲都有影响。如果不治疗,可能会导致胎儿水肿,此时应选择分娩和治疗心律失常。然而,如果胎儿未足月或接近足月,可能需要大剂量的抗心律失常药物才能实现足够的胎盘内生物利用度。尽管地高辛一直是治疗的主要药物,但氟卡尼或索他洛尔作为单一药物或与地高辛联合使用的治疗正在研究中。多学科团队管理以及医生和患者之间的共同决策是实现良好治疗效果的关键。在某些实践环境中,成人心脏病专家,特别是住院会诊服务或新兴的心内科-产科项目,可能会被要求评估或共同管理患有胎儿心律失常的孕妇。